Login / Signup

Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.

Roland HeinigRobert FrickeSebastian WertzJohannes NagelschmitzStephanie Loewen
Published in: European journal of drug metabolism and pharmacokinetics (2022)
Administration of finerenone 40 mg once daily confers no risk of clinically relevant drug-drug interactions with substrates of BCRP, OATP1B1, or OATP1B3. The potential for relevant inhibition of these transporters suggested by in vitro findings was not confirmed in vivo.
Keyphrases
  • adverse drug
  • drug induced
  • emergency department
  • physical activity